Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Methadone Maintenance & HIV Risk in Ukraine
This study is currently recruiting participants.
Verified by National Institute on Drug Abuse (NIDA), July 2008
Sponsored by: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00351026
  Purpose

Treatment of opioid dependence is an important way to reduce the spread of HIV and other infectious diseases, particularly in Ukraine since intravenous opioid use is the major way these infections are being spread. This proposal will be done at the Kiev City Narcology Hospital and the City AIDS Center with collaborators from the University of Alabama and the University of Colorado. It will study the acceptability and impact of a 3-month course of methadone maintenance on 50 persons with opioid dependence, 25 who are HIV+ and 25 HIV-. The proposed work will build on a relationship that was established with the Ukrainian Co-Principal Investigator, Sergiy Dvoryak, M.D., during his Humphrey Fellowship at Johns Hopkins in 1999-2000 when he spent time with Dr. Woody and Metzger at the Penn Addiction and Treatment and Research Center. It will also extend studies of pharmacologic treatment for opioid dependence and risk reduction behavioral interventions that are being done by Drs. Woody, Schumacher and Booth in Russia and Ukraine. Primary aims are to: measure the acceptability and compliance with a 3-month course of methadone maintenance in HIV+ and HIV- patients; measure the impact of a 3-month course of methadone in reducing opioid use in HIV+ and HIV- patients; measure the impact of a 3-month course of methadone on reducing HIV risk behavior in HIV+_and HIV- patients. Secondary aims are to: assess the degree to which a 3-month course of methadone maintenance reduces illegal activities and improves employment and psychiatric symptoms; determine short-term outcome after completion of methadone treatment; and obtain pilot data on the prevalence of hepatitis B and C among study patients. This study will provide pilot data on the acceptability and efficacy of a short-term course of methadone maintenance on HIV+ and HIV- persons in a setting where this treatment has not been evaluated, on the feasibility of conducting the kind of work that is proposed, and will enhance research capabilities of Kiev investigators for future HIV prevention and treatment studies.


Condition Intervention Phase
Opioid Dependence
Drug: Methadone
Phase III

MedlinePlus related topics: AIDS Hepatitis Hepatitis B
Drug Information available for: Methadone Methadone hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Official Title: Methadone Maintenance & HIV Risk in Ukraine

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Measure the acceptability and compliance with a 3-month course of methadone maintenance in HIV+ and HIV- patients in this cultural setting [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
  • Measure the impact of a 3-month course of methadone treatment in HIV+ and HIV- on reducing opioid use [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
  • Measure the impact of a 3-month course of methadone treatment in HIV+ and HIV- on reducing HIV risk behavior [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Assess the degree to which the 3-month course of methadone maintenance reduces illegal activities and improves employment and psychiatric symptoms [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
  • Determine short term outcome after completion of methadone treatment [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
  • Obtain pilot data on the prevalence of hepatitis B and C among study patients [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: February 2008
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
25 HIV negative opiate dependent patients all treated with methadone
Drug: Methadone
short-term methadone maintenance
2: Active Comparator
25 HIV positive opiate dependent patients all treated with methadone
Drug: Methadone
short-term methadone maintenance

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Primary diagnosis of current opioid dependence with physiological features, present for at least one year and seeking outpatient treatment.

Age between 18 and 40 Stable address within Kiev and not planning to move Home telephone number where can be reached Willingness and ability to give informed consent and otherwise participate

Exclusion Criteria:

Clinically significant cognitive impairment, schizophrenia, paranoid disorder, bipolar disorder, or seizure disorder Advanced neurological, cardiovascular, renal, hepatic or other medical disorder that would seriously impair or make hazardous patient's ability to participate Active tuberculosis Currently dependent on alcohol, benzodiazepines or other sedative-like drugs Pending legal charges with potential impending incarceration Plans to move from the area within the next 6 months Concurrent participation in another treatment study

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00351026

Locations
Ukraine
City AIDS Center Not yet recruiting
Kiev, Ukraine
Ukraine, 115
Kiev City AIDS Center Recruiting
Kiev, 115, Ukraine, 03115
Contact: Olexander Yurchenko, MD     (38044) 4509314     common@socio.kiev.ua    
Principal Investigator: Anatoliy M Viyevskiy, M.D., Ph.D.            
Sub-Investigator: Sergiy Dvoryak, M.D., Ph.D.            
Sponsors and Collaborators
  More Information

Responsible Party: University of Pennsylvania ( Office of Research Services )
Study ID Numbers: R21DA021073
Study First Received: July 10, 2006
Last Updated: July 25, 2008
ClinicalTrials.gov Identifier: NCT00351026  
Health Authority: United States: Federal Government

Keywords provided by National Institute on Drug Abuse (NIDA):
opioid dependence
methadone
HIV

Study placed in the following topic categories:
Naphazoline
Oxymetazoline
Methadone
Guaifenesin
Phenylephrine
Mental Disorders
HIV Infections
Acquired Immunodeficiency Syndrome
Substance-Related Disorders
Disorders of Environmental Origin
Phenylpropanolamine
Opioid-Related Disorders

Additional relevant MeSH terms:
Respiratory System Agents
Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Peripheral Nervous System Agents
Analgesics
Antitussive Agents
Central Nervous System Agents
Analgesics, Opioid
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009